⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618672 | 0.75 | — | — | |
| SCHEMBL3666402 | 0.75 | — | — | |
| SCHEMBL3632368 | 0.71 | — | — | |
| SCHEMBL2039431 | 0.60 | — | — | |
| SCHEMBL3971957 | 0.60 | NOS3 (0.34) | — | |
| SCHEMBL508556 | 0.60 | — | — | |
| SCHEMBL3628052 | 0.57 | — | — | |
| SCHEMBL588982 | 0.56 | — | — | |
| SCHEMBL253076 | 0.56 | — | — | |
| SCHEMBL946491 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350187-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Inc. (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2017046117-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | ABBVIE INC. (US) | 2017-03-23 | — | — | WO | claimed |
| EP-3089788-A1 | SERINE/THREONINE KINASE INHIBITORS | Genentech, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | claimed |
| WO-2015103133-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-07-09 | — | — | WO | claimed |
| EP-2820009-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2015-01-07 | — | — | EP | claimed |
| CN-102264722-B | Dihydropyridone amides as p2x7 modulators | HOFFMANN LA ROCHE | 2014-04-02 | — | — | CN | claimed |
| WO-2013130976-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-09-06 | — | — | WO | claimed |
| US-8163929-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-24 | — | — | US | claimed |
| CN-102264722-A | Dihydropyridone amides as p2x7 modulators | — | 2011-11-30 | — | — | CN | claimed |
| EP-2382202-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-11-02 | — | — | EP | claimed |
| WO-2010072607-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | claimed |
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | claimed |
| JP-2007518824-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | claimed |
| EP-1144384-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000043369-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| US-11186582-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | Dart Neuroscience, (Cayman) LTD. (KY) | 2021-11-30 | — | — | US | disclosed |
| EP-3818053-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20200095256-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC | 2020-03-26 | — | — | US | disclosed |
| EP-3350187-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046117-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | ABBVIE INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-3089788-A1 | SERINE/THREONINE KINASE INHIBITORS | Genentech, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103133-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
| EP-2820009-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| CN-102264722-B | Dihydropyridone amides as p2x7 modulators | HOFFMANN LA ROCHE | 2014-04-02 | — | — | CN | disclosed |
| WO-2013130976-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-8163929-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| CN-102264722-A | Dihydropyridone amides as p2x7 modulators | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2382202-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072607-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-1272478-A1 | SUBSTITUTED PHENYLURACILS | Bayer Aktiengesellschaft (DE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077084-A1 | SUBSTITUTED PHENYLURACILS | BAYER CROPSCIENCE AG (DE) | 2001-10-18 | — | — | WO | disclosed |
| EP-1144384-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043369-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-0898570-A1 | HERBICIDAL HETEROCYCLICALLY SUBSTITUTED BENZOYLISOTHIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997038996-A1 | HERBICIDAL HETEROCYCLICALLY SUBSTITUTED BENZOYLISOTHIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997038996-A1 | HERBICIDAL HETEROCYCLICALLY SUBSTITUTED BENZOYLISOTHIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-23 | — | — | WO | disclosed |